Uncategorized Archives - Page 11 of 19

WednesdayFeb 17, 2021 1:25 pm

QualityStocksNewsBreaks – TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) Announces Opening of Online Store

TAAT(TM) (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) today announced the opening of its online store where consumers in the U.S. can buy the company’s tobacco-free and nicotine-free alternative to traditional cigarettes. The update reads, “Residents of the United States will now be able to purchase TAAT(TM) online! Cartons of TAAT(TM) Original, Smooth, and Menthol can be ordered to addresses in most U.S. states. It's time for smokers aged 21+ to order TAAT(TM) and make the better choice!” To view the full press release, visit https://ibn.fm/w5UHx About TAAT(TM) Lifestyle & Wellness Ltd. The company has developed TAAT(TM), which is a tobacco-free…

ThursdayFeb 11, 2021 2:32 pm

QualityStocksNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Provides Update on Biopesticide Pipeline

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an innovative agriculture biotech company focused on providing natural biological protection for high value crops and other markets. Recently the company provided an update of its biopesticide product pipeline. The company — by extracting natural compounds from within the mustard seed — the mustard plant’s natural defense mechanism — has provided natural solutions to potentially replace widely used harmful synthetics that are being deregistered and banned. A recent article discussing this reads, “As part of the update, the company reported that a U.S. EPA registration already exists for its biopesticide product in…

WednesdayFeb 10, 2021 1:36 pm

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Achieves Record-Breaking Revenue for January 2021

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced record monthly gross revenue of $1,089,502 for January 2021. According to the update, January 2021’s revenue increased as compared to results for the month of December 2020 and during the highly dynamic holiday season, when the company achieved gross revenue of $1,029,883. January revenue exceeded management's expectations given that e-commerce sales were expected to be slower following the holiday season. This success during one of the slowest e-commerce periods of the year highlights the tremendous impact PlantX continues to have in the plant-based marketplace. "It is truly encouraging to…

TuesdayFeb 09, 2021 1:18 pm

QualityStocksNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Announces Bidi Vapor Received FDA PMTA Acceptance Letter for all 11 Bidi Stick Products

Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has announced that Bidi(R) Vapor has received a PMTA acceptance letter from the U.S. Food and Drug Administration (“FDA”). Kaival is the exclusive global distributor of Bidi Vapor LLC products. The PMTA letter marks an important milestone Bidi’s overall application is one step closer to meeting the FDA’s baseline criteria before moving into the substantive review, which is the final phase of the PMTA process. The PMTAa for Bidi Vapor now move on to the filing review…

WednesdayFeb 03, 2021 12:05 pm

QualityStocksNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) to Hold Extraordinary Meeting of Debentureholders

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has announced an upcoming shareholder meeting. The meeting, scheduled for 10 a.m. ET on Feb. 25, 2021, is an extraordinary meeting of holders of 8% unsecured convertible debentures that are due Feb. 28, 2021. Information containing detailed information regarding the amendments and resolutions to be considered during the meeting has been mailed to the company’s debentureholders of record. The meeting will be held virtually to maintain COVID-19 social distancing requirements; participants will be attending via a telephone conference. The announcement noted that the company’s…

WednesdayFeb 03, 2021 11:03 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. As part of its psychedelic pharmaceutical program, XPhyto needs industrial-scale production of standardized active pharmaceutical ingredients. This agreement is part of that strategic…

WednesdayJan 27, 2021 11:40 am

QualityStocksNewsBreaks – Amesite Inc. (NASDAQ: AMST) Acquires Spot on NABR List of 2020 Best and Brightest Companies to Work

Amesite (NASDAQ: AMST), an artificial intelligence (“AI”) software company providing online learning ecosystems for business, higher education, and K-12, this morning announced the receipt of two awards from the National Association for Business Resources (“NABR”). The NABR awards named Amesite one of the country's best places to work and a top leader in wellness. “I'm so proud of what our team has been able to accomplish during an historically challenging year,” Amesite founder and CEO Dr. Ann Marie Sastry stated in the news release. “To have us be recognized as one of the best and brightest places to work and also as a leader in…

ThursdayJan 14, 2021 12:08 pm

QualityStocksNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Enters Exclusive Sales Agreement; Offers Hemp, CBD Products in UK

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has finalized an exclusive sales agreement with Elements of Green, a European eCommerce marketplace for hemp CBD products. The agreement outlines the steps for PLUS to offer its products in the United Kingdom. Based on the agreement, PLUS Grapefruit CBD Uplift and Blueberry CBD Balance gummies, which are 100% hemp, are now available in the UK exclusively through Elements of Green. Elements of Green is a European eCommerce marketplace for lab-tested CBD products and offers an impressive lineup of premium hemp-based CBD products in…

WednesdayJan 13, 2021 12:45 pm

QualityStocksNewsBreaks – Knightscope Inc. Secures Grocery Contract

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), announced that it has entered into a contract to deploy in a national grocery chain. According to the California Grocers Association, shoplifting and organized retail crime have been on the rise, amounting to significant losses and threatening the safety of employees and customers. Knightscope’s solution will assist to reduce the burden on retailers. This will be Knightscope’s first deployment at a major grocery store and, if history repeats itself, it suspects that other similar retailers will be looking at the results for possible inclusion in their…

MondayJan 04, 2021 2:34 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis…

Site Search

Company Search

Category: Uncategorized